Nuclear Medicine Market by Product, Application and Geography - Forecast and Analysis 2023-2027
- Published: Mar 2023
- Pages: 169
- SKU: IRTNTR75093
Enjoy complimentary customisation on priority with our Enterprise License!
Single:
One user only.
Quick & easy download optionEnterprise:
Unlimited user access (Within your organization)
Complimentary Customization Included
The nuclear medicine market is estimated to grow at a CAGR of 16.48% between 2022 and 2027. The size of the market is forecast to increase by USD 8,057.89 million. The growth of the market depends on several factors, including the growing adoption of SPECT/CT hybrid imaging systems, the increased use of nuclear medicine for detecting diseases at an early stage, and the growing cancer cases and rising investment in the oncology market.
This report extensively covers market segmentation by product (radiotherapeutics, equipment SPECT and PET), application (oncology, cardiology, neurology, and others.), and geography (North America, Asia, Europe, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.
What will be the size of the Nuclear Medicine Market During the Forecast Period?
To learn more about this report, Download Report Sample
Nuclear Medicine Market: Key Drivers, Trends, Challenges, and Customer Landscape
The growing adoption of SPECT/CT hybrid imaging systems is notably driving the market growth, although factors such as the regulatory hurdles regarding the preparation of radiopharmaceuticals may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Key Nuclear Medicine Market Driver
The growing adoption of SPECT/CT hybrid imaging systems is the key factor driving the growth of the global nuclear medicine market. The market is increasingly adopting SPECT/CT hybrid imaging technology due to the following advantages, such as early diagnosis, accurate disease staging, and effective response to the treatment of chronic conditions such as diabetes. The growing demand for hybrid SPECT/CT imaging systems is also due to technological advances, falling prices, increased end-user awareness, and better reimbursement policies. Additionally, combined SPECT/CT scans provide images that identify the anatomical location of an individual's metabolic activity.
Moreover, vendors are improving their technological capabilities of SPECT/CT hybrid imaging systems. This will further increase the adoption of SPECT/CT hybrid imaging across the globe. Some new technological capabilities include more precise measurement of tumors for better differentiation, increased data storage capabilities for oncologists to track tumor developments, and less patient movement. Vendors are also providing low-cost SPECT/CT hybrid imaging systems. Thus, the growing adoption of SPECT/CT hybrid imaging systems will positively impact the growth of the market during the forecast period.
Significant Nuclear Medicine Market Trend
Minimal side effects of radiopharmaceuticals as compared with their potential benefits are the primary trend in the global nuclear medicine market growth. Radiopharmaceuticals have fewer side effects than their potential benefits. This is one of the main reasons why nuclear medicine is recommended for various diagnostic and therapeutic purposes. There are currently no known long-term side effects from low-dose exposure to radiopharmaceuticals. Some health hazards may be caused owing to radiopharmaceuticals, such as soreness, bleeding, and swelling at the site of injection, but these are quite rarely observed. The National Institutes of Health (NIH) states that approximately 1 to 6 reactions have been observed for every 100,000 injections.
Also, the NIH stated that the rate of adverse effects was 1 in 400 cases for the lung visualization agent macro aggregated albumin and 1 in 800 cases for bone-seeking radiopharmaceutical methylene diphosphonate. The low rates of adverse effects of radiopharmaceuticals are mainly owing to the use of a small amount of the drug during various processes such as cancer treatment. Also, radiopharmaceuticals are used for their specific localized action produced owing to the physiologic mechanism and not for any pharmacological action, and hence pharmacologic action is not anticipated from it.
Major Nuclear Medicine Market Challenge
Regulatory hurdles regarding the preparation of radiopharmaceuticals are a major challenge to the growth of the global nuclear medicine market. In the United States, the FDA and the American College of Radiology Imaging Network have developed an approach for the approval of new radiopharmaceuticals by comparing them to standard molecules. When the US FDA is convinced regarding the safety and efficacy of the molecule, the product is approved for marketing. Owing to extensive toxicology testing, the radiopharmaceutical compound undergoes additional scrutiny and approval pathway. If unsatisfied, the US FDA may request additional clinical trials from the vendor, which imposes a financial burden on the vendor.
Hence, there are very few nuclear medicines approved by the US FDA. In addition, radio-pharmacy regulations vary in European countries. Vendors need to submit their clinical research data separately, which then go through different regulatory policies in Europe. In addition to the approval of nuclear medicines, regulatory agencies are strict regarding the handling of radioactive materials. The transportation of radioactive materials is also expensive, which has restricted the distribution of PET in Japan. Strict regulations and expensive transportation of nuclear medicines may inhibit the entry of new vendors into the market, thereby will pose a threat to the growth of the market during the forecast period.
Key Nuclear Medicine Market Customer Landscape
The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Nuclear Medicine Market Customer Landscape
Who are the Major Nuclear Medicine Market Vendors?
Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
ECZACIBASI MONROL NUCLEAR PRODUCTS CO.: The company offers nuclear medicine such as Lutetium Chloride nca. Also, the company develops nuclear medicines with high-quality radiopharmaceuticals.
The report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:
- Bayer AG
- Bracco Spa
- Cardinal Health Inc.
- Eckert and Ziegler AG
- GE Healthcare Technologies Inc.
- IBA Radiopharma Solutions
- Jubilant Pharmova Ltd.
- Koninklijke Philips NV
- Lantheus Holdings Inc.
- Mallinckrodt Plc
- Medi-Radiopharma
- Mirion Technologies Inc.
- Necsa
- Novartis AG
- Siemens Healthineers AG
Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
What is the Fastest-Growing Segments in the Nuclear Medicine Market?
The market share growth by the radiotherapeutics segment will be significant during the forecast period. Radiopharmaceuticals are pharmaceuticals drugs having radioactive properties. These are made up of a radioisotope that bonds to an organic molecule. Radiopharmaceutical drugs can be used for therapeutic and diagnostic purposes. These are also used to treat multiple disease sites, such as cancer and cardiac diseases. Such factors will increase segment growth during the forecast period.
Get a glance at the market contribution of various segments Request a PDF Sample
The radiotherapeutics segment was valued at USD 1,880.57 million in 2017 and continue to grow by 2021. Radiopharmaceuticals have been known for their therapeutic uses for decades. Recently, the rapid growth of nuclear medicine research and development activities has contributed to the growth of this field with the introduction of new radiopharmaceuticals and radionucleotides for the treatment of neuroendocrine and metastatic bone pain and tumors (both malignant and non-malignant). The radiopharmaceutical segment has a high growth rate and is poised for greater growth and development during the forecast period. The increasing prevalence of various diseases such as cancer and thyroid will increase the demand for new treatments. Such factors are expected to have a positive impact on the growth of the radiopharmaceutical segment of the global nuclear medicine market during the forecast period.
Which are the Key Regions for the Nuclear Medicine Market?
For more insights on the market share of various regions Request PDF Sample now!
North America is estimated to contribute 45% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. North America is the dominant region in the global nuclear medicine market, with the United States and Canada being the major revenue-generating countries. Moreover, the changes in hospital infrastructure and healthcare policies are boosting the growth of the market. The trend towards hybrid operating rooms and healthcare cloud computing are some of the influencing factors underpinning the revenue growth of the market. Factors such as the low cost of SPECT scanners and technological developments are influencing the rapid adoption of SPECT scanning systems, increasing the demand for nuclear medicine in the region. The standalone SPECT system is one of the oldest and most widely used medical imaging devices on the market and is widely used throughout the region. Such factors will increase the market growth in this region during the forecast period.
In 2020, the outbreak of COVID-19 adversely affected all countries in North America, especially the US. However, with the initiation of vaccination drives in 2021, the number of COVID-19 cases decreased in the region, which led to the resumption of pharmaceutical industry operations. The rising number of cancer cases and the presence of well-established vendors for such products in this region will boost the growth of the nuclear medicine market in the region during the forecast period.
Segment Overview
The report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
- Product Outlook (USD Million, 2017 - 2027)
- Radiotherapeutics
- Equipment SPECT and PET
- Application Outlook (USD Million, 2017 - 2027)
- Oncology
- Cardiology
- Neurology
- Others
- Region Outlook (USD Million, 2017 - 2027)
- North America
- The U.S.
- Canada
- Europe
- The U.K.
- Germany
- France
- Rest of Europe
- Asia
- China
- India
- ROW
- Australia
- Argentina
- Rest of the world
- North America
Parent Market Analysis
Technavio categorizes the global nuclear medicine market as a part of the pharmaceutical market within the overall healthcare industry. The parent pharmaceuticals market covers products and companies engaged in the R&D or production of generic drugs, non-generic drugs, and veterinary drugs. Our research report has extensively covered external factors influencing the parent market growth during the forecast period.
|
Nuclear Medicine Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
169 |
|
Base year |
2022 |
|
Historic period |
2017-2021 |
|
Forecast period |
2023-2027 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 16.48% |
|
Market growth 2023-2027 |
USD 8,057.89 million |
|
Market structure |
Fragmented |
|
YoY growth 2022-2023(%) |
14.03 |
|
Regional analysis |
North America, Asia, Europe, and Rest of World (ROW) |
|
Performing market contribution |
North America at 45% |
|
Key countries |
US, Germany, UK, Japan, and China |
|
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Bayer AG, Bracco Spa, Cardinal Health Inc., Eckert and Ziegler AG, ECZACIBASI MONROL NUCLEAR PRODUCTS CO., GE Healthcare Technologies Inc., IBA Radiopharma Solutions, Jubilant Pharmova Ltd., Koninklijke Philips NV, Lantheus Holdings Inc., Mallinckrodt Plc, Medi-Radiopharma , Mirion Technologies Inc., Necsa, Novartis AG, Siemens Healthineers AG, Sirtex Medical Pty Ltd., Telix Pharmaceuticals Ltd., Tema Sinergie SpA, and TTG Imaging Solutions LLC |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period. |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
What are the Key Data Covered in this Nuclear Medicine Market Report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the growth of the nuclear medicine market between 2023 and 2027
- Precise estimation of the size of the nuclear medicine market size and its contribution to the parent market
- Accurate predictions about upcoming trends and changes in consumer behavior
- Growth of the market industry across North America, Asia, Europe, and Rest of World (ROW)
- Thorough analysis of the market’s competitive landscape and detailed information about vendors
- Comprehensive analysis of factors that will challenge the growth of nuclear medicine market vendors
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Application
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 13: Market segments
- 3.3 Market size 2022
- 3.4 Market outlook: Forecast for 2022-2027
- Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
4 Historic Market Size
- 4.1 Global nuclear medicine market 2017 - 2021
- Exhibit 18: Historic Market Size – Data Table on Global nuclear medicine market 2017 - 2021 ($ million)
- 4.2 Product Segment Analysis 2017 - 2021
- Exhibit 19: Historic Market Size – Product Segment 2017 - 2021 ($ million)
- 4.3 Application Segment Analysis 2017 - 2021
- Exhibit 20: Historic Market Size – Application Segment 2017 - 2021 ($ million)
- 4.4 Geography Segment Analysis 2017 - 2021
- Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)
- 4.5 Country Segment Analysis 2017 - 2021
- Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)
5 Five Forces Analysis
- 5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
- 5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
- 5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
- 5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
- 5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
- 5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
- 5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2022 and 2027
6 Market Segmentation by Product
- 6.1 Market segments
- Exhibit 30: Chart on Product - Market share 2022-2027 (%)
- Exhibit 31: Data Table on Product - Market share 2022-2027 (%)
- 6.2 Comparison by Product
- Exhibit 32: Chart on Comparison by Product
- Exhibit 33: Data Table on Comparison by Product
- 6.3 Radiotherapeutics - Market size and forecast 2022-2027
- Exhibit 34: Chart on Radiotherapeutics - Market size and forecast 2022-2027 ($ million)
- Exhibit 35: Data Table on Radiotherapeutics - Market size and forecast 2022-2027 ($ million)
- Exhibit 36: Chart on Radiotherapeutics - Year-over-year growth 2022-2027 (%)
- Exhibit 37: Data Table on Radiotherapeutics - Year-over-year growth 2022-2027 (%)
- 6.4 Equipment (SPECT and PET) - Market size and forecast 2022-2027
- Exhibit 38: Chart on Equipment (SPECT and PET) - Market size and forecast 2022-2027 ($ million)
- Exhibit 39: Data Table on Equipment (SPECT and PET) - Market size and forecast 2022-2027 ($ million)
- Exhibit 40: Chart on Equipment (SPECT and PET) - Year-over-year growth 2022-2027 (%)
- Exhibit 41: Data Table on Equipment (SPECT and PET) - Year-over-year growth 2022-2027 (%)
- 6.5 Market opportunity by Product
- Exhibit 42: Market opportunity by Product ($ million)
- Exhibit 43: Data Table on Market opportunity by Product ($ million)
7 Market Segmentation by Application
- 7.1 Market segments
- Exhibit 44: Chart on Application - Market share 2022-2027 (%)
- Exhibit 45: Data Table on Application - Market share 2022-2027 (%)
- 7.2 Comparison by Application
- Exhibit 46: Chart on Comparison by Application
- Exhibit 47: Data Table on Comparison by Application
- 7.3 Oncology - Market size and forecast 2022-2027
- Exhibit 48: Chart on Oncology - Market size and forecast 2022-2027 ($ million)
- Exhibit 49: Data Table on Oncology - Market size and forecast 2022-2027 ($ million)
- Exhibit 50: Chart on Oncology - Year-over-year growth 2022-2027 (%)
- Exhibit 51: Data Table on Oncology - Year-over-year growth 2022-2027 (%)
- 7.4 Cardiology - Market size and forecast 2022-2027
- Exhibit 52: Chart on Cardiology - Market size and forecast 2022-2027 ($ million)
- Exhibit 53: Data Table on Cardiology - Market size and forecast 2022-2027 ($ million)
- Exhibit 54: Chart on Cardiology - Year-over-year growth 2022-2027 (%)
- Exhibit 55: Data Table on Cardiology - Year-over-year growth 2022-2027 (%)
- 7.5 Neurology - Market size and forecast 2022-2027
- Exhibit 56: Chart on Neurology - Market size and forecast 2022-2027 ($ million)
- Exhibit 57: Data Table on Neurology - Market size and forecast 2022-2027 ($ million)
- Exhibit 58: Chart on Neurology - Year-over-year growth 2022-2027 (%)
- Exhibit 59: Data Table on Neurology - Year-over-year growth 2022-2027 (%)
- 7.6 Others - Market size and forecast 2022-2027
- Exhibit 60: Chart on Others - Market size and forecast 2022-2027 ($ million)
- Exhibit 61: Data Table on Others - Market size and forecast 2022-2027 ($ million)
- Exhibit 62: Chart on Others - Year-over-year growth 2022-2027 (%)
- Exhibit 63: Data Table on Others - Year-over-year growth 2022-2027 (%)
- 7.7 Market opportunity by Application
- Exhibit 64: Market opportunity by Application ($ million)
- Exhibit 65: Data Table on Market opportunity by Application ($ million)
8 Customer Landscape
- 8.1 Customer landscape overview
- Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
- 9.1 Geographic segmentation
- Exhibit 67: Chart on Market share by geography 2022-2027 (%)
- Exhibit 68: Data Table on Market share by geography 2022-2027 (%)
- 9.2 Geographic comparison
- Exhibit 69: Chart on Geographic comparison
- Exhibit 70: Data Table on Geographic comparison
- 9.3 North America - Market size and forecast 2022-2027
- Exhibit 71: Chart on North America - Market size and forecast 2022-2027 ($ million)
- Exhibit 72: Data Table on North America - Market size and forecast 2022-2027 ($ million)
- Exhibit 73: Chart on North America - Year-over-year growth 2022-2027 (%)
- Exhibit 74: Data Table on North America - Year-over-year growth 2022-2027 (%)
- 9.4 Asia - Market size and forecast 2022-2027
- Exhibit 75: Chart on Asia - Market size and forecast 2022-2027 ($ million)
- Exhibit 76: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
- Exhibit 77: Chart on Asia - Year-over-year growth 2022-2027 (%)
- Exhibit 78: Data Table on Asia - Year-over-year growth 2022-2027 (%)
- 9.5 Europe - Market size and forecast 2022-2027
- Exhibit 79: Chart on Europe - Market size and forecast 2022-2027 ($ million)
- Exhibit 80: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
- Exhibit 81: Chart on Europe - Year-over-year growth 2022-2027 (%)
- Exhibit 82: Data Table on Europe - Year-over-year growth 2022-2027 (%)
- 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
- Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- 9.7 US - Market size and forecast 2022-2027
- Exhibit 87: Chart on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 88: Data Table on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 89: Chart on US - Year-over-year growth 2022-2027 (%)
- Exhibit 90: Data Table on US - Year-over-year growth 2022-2027 (%)
- 9.8 Japan - Market size and forecast 2022-2027
- Exhibit 91: Chart on Japan - Market size and forecast 2022-2027 ($ million)
- Exhibit 92: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
- Exhibit 93: Chart on Japan - Year-over-year growth 2022-2027 (%)
- Exhibit 94: Data Table on Japan - Year-over-year growth 2022-2027 (%)
- 9.9 China - Market size and forecast 2022-2027
- Exhibit 95: Chart on China - Market size and forecast 2022-2027 ($ million)
- Exhibit 96: Data Table on China - Market size and forecast 2022-2027 ($ million)
- Exhibit 97: Chart on China - Year-over-year growth 2022-2027 (%)
- Exhibit 98: Data Table on China - Year-over-year growth 2022-2027 (%)
- 9.10 Germany - Market size and forecast 2022-2027
- Exhibit 99: Chart on Germany - Market size and forecast 2022-2027 ($ million)
- Exhibit 100: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
- Exhibit 101: Chart on Germany - Year-over-year growth 2022-2027 (%)
- Exhibit 102: Data Table on Germany - Year-over-year growth 2022-2027 (%)
- 9.11 UK - Market size and forecast 2022-2027
- Exhibit 103: Chart on UK - Market size and forecast 2022-2027 ($ million)
- Exhibit 104: Data Table on UK - Market size and forecast 2022-2027 ($ million)
- Exhibit 105: Chart on UK - Year-over-year growth 2022-2027 (%)
- Exhibit 106: Data Table on UK - Year-over-year growth 2022-2027 (%)
- 9.12 Market opportunity by geography
- Exhibit 107: Market opportunity by geography ($ million)
- Exhibit 108: Data Tables on Market opportunity by geography ($ million)
10 Drivers, Challenges, and Trends
- 10.1 Market drivers
- 10.2 Market challenges
- 10.3 Impact of drivers and challenges
- Exhibit 109: Impact of drivers and challenges in 2022 and 2027
- 10.4 Market trends
11 Vendor Landscape
- 11.1 Overview
- 11.2 Vendor landscape
- Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
- 11.3 Landscape disruption
- Exhibit 111: Overview on factors of disruption
- 11.4 Industry risks
- Exhibit 112: Impact of key risks on business
12 Vendor Analysis
- 12.1 Vendors covered
- Exhibit 113: Vendors covered
- 12.2 Market positioning of vendors
- Exhibit 114: Matrix on vendor position and classification
- 12.3 Bayer AG
- Exhibit 115: Bayer AG - Overview
- Exhibit 116: Bayer AG - Business segments
- Exhibit 117: Bayer AG - Key news
- Exhibit 118: Bayer AG - Key offerings
- Exhibit 119: Bayer AG - Segment focus
- 12.4 Bracco Spa
- Exhibit 120: Bracco Spa - Overview
- Exhibit 121: Bracco Spa - Product / Service
- Exhibit 122: Bracco Spa - Key offerings
- 12.5 Cardinal Health Inc.
- Exhibit 123: Cardinal Health Inc. - Overview
- Exhibit 124: Cardinal Health Inc. - Business segments
- Exhibit 125: Cardinal Health Inc. - Key news
- Exhibit 126: Cardinal Health Inc. - Key offerings
- Exhibit 127: Cardinal Health Inc. - Segment focus
- 12.6 Eckert and Ziegler AG
- Exhibit 128: Eckert and Ziegler AG - Overview
- Exhibit 129: Eckert and Ziegler AG - Business segments
- Exhibit 130: Eckert and Ziegler AG - Key news
- Exhibit 131: Eckert and Ziegler AG - Key offerings
- Exhibit 132: Eckert and Ziegler AG - Segment focus
- 12.7 ECZACIBASI MONROL NUCLEAR PRODUCTS CO.
- Exhibit 133: ECZACIBASI MONROL NUCLEAR PRODUCTS CO. - Overview
- Exhibit 134: ECZACIBASI MONROL NUCLEAR PRODUCTS CO. - Product / Service
- Exhibit 135: ECZACIBASI MONROL NUCLEAR PRODUCTS CO. - Key offerings
- 12.8 GE Healthcare Technologies Inc.
- Exhibit 136: GE Healthcare Technologies Inc. - Overview
- Exhibit 137: GE Healthcare Technologies Inc. - Business segments
- Exhibit 138: GE Healthcare Technologies Inc. - Key offerings
- Exhibit 139: GE Healthcare Technologies Inc. - Segment focus
- 12.9 IBA Radiopharma Solutions
- Exhibit 140: IBA Radiopharma Solutions - Overview
- Exhibit 141: IBA Radiopharma Solutions - Business segments
- Exhibit 142: IBA Radiopharma Solutions - Key offerings
- Exhibit 143: IBA Radiopharma Solutions - Segment focus
- 12.10 Jubilant Pharmova Ltd.
- Exhibit 144: Jubilant Pharmova Ltd. - Overview
- Exhibit 145: Jubilant Pharmova Ltd. - Business segments
- Exhibit 146: Jubilant Pharmova Ltd. - Key news
- Exhibit 147: Jubilant Pharmova Ltd. - Key offerings
- Exhibit 148: Jubilant Pharmova Ltd. - Segment focus
- 12.11 Koninklijke Philips NV
- Exhibit 149: Koninklijke Philips NV - Overview
- Exhibit 150: Koninklijke Philips NV - Business segments
- Exhibit 151: Koninklijke Philips NV - Key news
- Exhibit 152: Koninklijke Philips NV - Key offerings
- Exhibit 153: Koninklijke Philips NV - Segment focus
- 12.12 Mallinckrodt Plc
- Exhibit 154: Mallinckrodt Plc - Overview
- Exhibit 155: Mallinckrodt Plc - Business segments
- Exhibit 156: Mallinckrodt Plc - Key news
- Exhibit 157: Mallinckrodt Plc - Key offerings
- Exhibit 158: Mallinckrodt Plc - Segment focus
- 12.13 Medi-Radiopharma
- Exhibit 159: Medi-Radiopharma - Overview
- Exhibit 160: Medi-Radiopharma - Product / Service
- Exhibit 161: Medi-Radiopharma - Key offerings
- 12.14 Necsa
- Exhibit 162: Necsa - Overview
- Exhibit 163: Necsa - Product / Service
- Exhibit 164: Necsa - Key offerings
- 12.15 Novartis AG
- Exhibit 165: Novartis AG - Overview
- Exhibit 166: Novartis AG - Business segments
- Exhibit 167: Novartis AG - Key offerings
- Exhibit 168: Novartis AG - Segment focus
- 12.16 Siemens Healthineers AG
- Exhibit 169: Siemens Healthineers AG - Overview
- Exhibit 170: Siemens Healthineers AG - Business segments
- Exhibit 171: Siemens Healthineers AG - Key news
- Exhibit 172: Siemens Healthineers AG - Key offerings
- Exhibit 173: Siemens Healthineers AG - Segment focus
- 12.17 Sirtex Medical Pty Ltd.
- Exhibit 174: Sirtex Medical Pty Ltd. - Overview
- Exhibit 175: Sirtex Medical Pty Ltd. - Product / Service
- Exhibit 176: Sirtex Medical Pty Ltd. - Key offerings
13 Appendix
- 13.1 Scope of the report
- 13.2 Inclusions and exclusions checklist
- Exhibit 177: Inclusions checklist
- Exhibit 178: Exclusions checklist
- 13.3 Currency conversion rates for US$
- Exhibit 179: Currency conversion rates for US$
- 13.4 Research methodology
- Exhibit 180: Research methodology
- Exhibit 181: Validation techniques employed for market sizing
- Exhibit 182: Information sources
- 13.5 List of abbreviations
- Exhibit 183: List of abbreviations
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
- Manufacturers and suppliers
- Channel partners
- Industry experts
- Strategic decision makers
Secondary sources
- Industry journals and periodicals
- Government data
- Financial reports of key industry players
- Historical data
- Press releases
DATA ANALYSIS
Data Synthesis
- Collation of data
- Estimation of key figures
- Analysis of derived insights
Data Validation
- Triangulation with data models
- Reference against proprietary databases
- Corroboration with industry experts
REPORT WRITING
Qualitative
- Market drivers
- Market challenges
- Market trends
- Five forces analysis
Quantitative
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
Frequently Asked Questions?
- US
- Germany
- UK
- Japan
- China
- Growing adoption of SPECT/CT hybrid imaging systems
- Minimal side effects of the radiopharmaceuticals as compared with its potential benefits
Key Questions Answered
- What are the key global market and the regional market share?
- What are the revenue-generating key market segments?
- What are the key factors driving and challenging this market’s growth?
- Who are the key market vendors and their growth strategies?
- What are the latest trends influencing the growth of this market?
- What are the variables influencing the market growth in the primary regions?
- What are the factors influencing the growth of the parent market?
Why should you prefer Technavio's market insights report?
Certified ISO 9001 : 2015
We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.
We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.
Single:
One user only.
Quick & easy download optionEnterprise:
Unlimited user access (Within your organization)
Complimentary Customization Included
2500 USD
Get the report (PDF) sent to your email within minutes.
Subscribe & Save
Get lifetime access to our
Technavio Insights
Did you know?
Did you know?
Did you know?
Customized Report as per your Business Needs
- Our analysts will work directly with you and understand your needs
- Get data on specified regions or segments, competitor and Vendors
- Data will be formatted and presented as per your requirements
- We offer $1000 worth of FREE customization at the time of purchase
Let us help you make report more suited to your requirements.
- Get a competitive breakdown as per your niche industry
- Customize the data with various metrics that meet your business prerequisite
- Understand Revenue Sources, Customers and many more
- Details on Market Share
- These customizations are done in a short amount of time by our analysts and industry experts
